Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Fifty 410 vs AskRx

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #263

Fifty 410

Cost-first shoppers who want a one-time-payment compounded tirzepatide bundle, understanding the 'per month' figure is really a 3-month lump sum.

Visit Fifty 410
VS
Grade C · #266

AskRx

Patients who specifically want FDA-approved branded Wegovy/Zepbound/Foundayo and don't need to see the drug price before starting intake.

Visit AskRx

The verdict

Too close to callGrade C vs C

Fifty 410 and AskRx tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with Fifty 410 (ranked #263, a hair above #266) — Cost-first shoppers who want a one-time-payment compounded tirzepatide bundle, understanding the 'per month' figure is really a 3-month lump sum. But AskRx is a genuine coin-flip alternative here.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Fifty 410.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

57
45

Price Transparency

94
54

Nationwide Access

24
86

Formulation Options

66
64

Clinical Oversight

68
82

Contract Flexibility

37
20

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecFifty 410AskRx
Cost-Efficiency Index59/10059/100
Semaglutide / mo$199/mo (all doses, compounded)Not disclosed
Tirzepatide / mo$133/mo (starting dose, 3-month plan, compounded)Not disclosed
Semaglutide / yr (modeled)$2,388
Tirzepatide / yr (modeled)$1,596
CoverageCoverage not publishedAll 50 states
Oral / sublingualNoYes
Brand-name accessCompounded onlyYes
Rank here#263#266

Fifty 410

59/100

Where the value is

  • No recurring subscription — you pay once per order and are not auto-billed
  • Transparent per-tier tirzepatide totals ($399/$499/$549) shown alongside the per-month math, so the real charge is visible if you read past the headline
  • Free overnight/2-day shipping and refrigerated packaging included in every tier

The tradeoffs

  • Tirzepatide's advertised '$133/month' is a 3-month prepay of $399 charged in one transaction, not a monthly recurring price — the cheapest advertised number is not what most shoppers will assume
  • Semaglutide has no discounted multi-month tier and, at $199 flat, actually costs more per month than tirzepatide's cheapest bundle
Visit Fifty 410

Full Fifty 410 review →

Regulatory note: the FDA issued a warning letter to Aspen Aesthetics dba Fifty 410 in February 2026. We still list and link to Fifty 410; you should know the letter is on the public record before you decide.

AskRx

59/100

Where the value is

  • Sells only FDA-approved branded medication ('never compounded'), removing compounding-related sourcing questions entirely
  • States a clear, itemized flat care fee ($90 visit + $10 fulfillment = $100/mo) rather than folding an undisclosed markup into the drug price
  • Explicitly states no markup is added to the medication's pharmacy cost

The tradeoffs

  • The actual medication price — the majority of the real monthly cost for a brand-name GLP-1 — is never published; it's shown only at checkout after intake, so the site cannot be used to comparison-shop the true total cost
  • Live video visits are limited to 'select states' despite the blanket '50 States' coverage claim, an inconsistency the site doesn't reconcile
Visit AskRx

Full AskRx review →

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons